tbuckley/cabot-search huggingface dataset:
Concerns Regarding a Meta-analysis Comparing Psychotherapy with Medications for Posttraumatic Stress Disorder—Reply
Authors: Heike Gerger
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose
Authors: Zhenyu Luo, Hao Tian, Lanlan Liu, Zhikuan Chen, Ruijing Liang, Ze Chen, Zhihao Wu, Aiqing Ma, Mingbin Zheng, Lintao Cai
Journal: Theranostics (2018)

Hypoxia is a characteristic feature of solid tumors and an important causation of resistance to chemotherapy and photodynamic therapy (PDT).It is challenging to develop efficient functional nanomaterials for tumor oxygenation and therapeutic applications.Methods: Through disulfide reconfiguration to hybridize hemoglobin and albumin, tumor-targeted hybrid protein oxygen carriers (HPOCs) were fabricated, serving as nanomedicines for precise tumor oxygenation and simultaneous enhancement of hypoxia-dampened chemotherapy and photodynamic therapy.Based on encapsulation of doxorubicin (DOX) and chlorin e6 (Ce6) into HPOCs to form ODC-HPOCs, the mechanism and therapeutic efficacy of oxygen-enhanced chemo-PDT was investigated in vitro and in vivo.Results: The precise oxygen preservation and release of the HPOC guaranteed sufficient tumor oxygenation, which is able to break hypoxia-induced chemoresistance by downregulating the expressions of hypoxia-inducible factor-1α (HIF-1α), multidrug resistance 1 (MDR1) and P-glycoprotein (P-gp), resulting in minimized cellular efflux of chemodrug.Moreover, the oxygen supply is fully exploited for upgrading the generation of reactive oxygen species (ROS) during the photodynamic process.As a result, only a single-dose treatment of the HPOCs-based chemo-PDT exhibited superior tumor suppression.The combination therapy was guided by in vivo fluorescence/photoacoustic imaging with nanoparticle tracking and oxygen monitoring.Conclusion: This well-defined HPOC as a versatile nanosystem is expected to pave a new way for breaking multiple hypoxia-induced therapeutic resistances to achieve highly effective treatment of solid tumors.
A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial
Authors: R. Labianca, G. Rosati, N. Fazio, L. Cavanna, D. Ferrari, M Di Bartolomeo, S. Mosconi, M. Giordano, N. Silvestris, F. Artioli, R.V. Iaffaioli, E.A. Veltri, D. Amoroso, A. Ciarlo, S. Barni, S. Cascinu, C. Davite, A Di Sanzo, A. Casolaro
Journal: Annals of Oncology (2019)
Concomitant administration of weekly oxaliplatin, 5FU continuous infusion and radiotherapy in locally advanced pancreatic cancer (LAPC): A GERCOR phase II study
Authors: L. Moureau-Zabotto, J. Phélip, P. Afchain, L. Mineur, T. André, V. Vendrely, G. Lledo, O. Dupuis, E. Touboul, J. Balosso
Journal: Journal of Clinical Oncology (2006)

4039 Background: According to previous GERCOR studies in LAPC, concomitant chemoradiation therapy (CCRT) is indicated for non-progressive patients (pts) after systemic chemotherapy (CT). In order to improve the results of a classical 5FU-based CCRT, this study was designed to assess the efficacy and toxicity of weekly oxaliplatin (Ox), 5FU continuous infusion (c.i.) and radiation therapy (RT) in LAPC pts. Methods: Eligibility criteria included non resectable pathologically-proven LAPC, age &gt; 18 yrs, PS &lt; 2, and no prior CT or RT. All patients were first treated with 4 cycles of GEMOX (gemcitabine 1000 mg/m 2 , 100 min IV, d1; Ox 100 mg/m 2 , 2h IV, d2, every 2 wk). One month after cycle 4, non-progressive pts with PS &lt; 2 received 45 Gy (25 fractions, 5 d/wk) + 10 Gy (concomitant boost in macroscopic tumor during wks 4 &amp; 5, six hours apart large volume irradiation), combined with 250 mg/m 2 /d 5FU c.i. and weekly Ox. Initial 50 mg/m 2 Ox dose was increased to 60 mg/m 2 in absence of unacceptable toxicity after the 3 first included pts. Results: 60 pts were included (29 F/ 31 M, age 65.8 ± 9.6 yrs, range 37 - 80). 50 pts (83%) received CCRT, while 10 did not for the following reasons: metastatic progression (7 pts), OMS&gt;2 (1), and CT toxicity (2). 44 pts (73 %) received the full planned CCRT dose-intensity. NCI-CTC grade 3–4 toxicities during CCRT and the following month (% of pts) were : neutropenia (14%), thrombocytopenia (10%), nausea-vomiting (20%), diarrhea (12%) and neuropathy (2%). 2 toxic deaths occurred during CCRT. With a median follow up of 15 mo, median progression-free survival (PFS) and overall survival (OS) of the whole population were 7.6 mo and 13.8 mo, respectively. For pts who received CCRT, median PFS and OS were 9.4 and 13.9 mo, respectively (2.6 and 9.9 mo, respectively, for pts who did not received CCRT). Conclusion: Chemotherapy before CCRT can identify pts who might potentially benefit of CCRT. Concomitant administration of weekly Ox, continuous IV FU and RT in LAPC is feasible with an acceptable toxicity. The results in terms of PFS and OS compare favourably with a classical 5FU-based CCRT. [Table: see text]
FDA recalls ranitidine medicines over potential cancer causing impurity
Authors: Elisabeth Mahase
Journal: BMJ (2019)

The US Food and Drug Administration has asked doctors and patients to return certain batches of over-the-counter ranitidine tablets (75 mg and 150 mg), after low levels of the probable human carcinogen N -nitrosodimethylamine (NDMA) were detected.1

The FDA released updates to the public and doctors explaining that some ranitidine medicines might contain low levels of NDMA and asked for any tablets labelled by Walgreens, Walmart, or Rite-Aid …
Abstract MP14: Trends in Stroke Incidence Among Older Adults- ARIC 1990-2016
Authors: Silvia Koton, Yingying Sang, Andrea L Schneider, Wayne D Rosamond, Rebecca F Gottesman, Josef Coresh
Journal: Circulation (2019)

Introduction: Stroke incidence has generally declined in the last decades in the US. Using validated stroke data in the Atherosclerosis Risk in Communities (ARIC) study, we have previously shown decreasing stroke incidence rates from 1987 to 2011 among ≥65 years old (JAMA 2014). We evaluated whether stroke incidence declines among older adults continued during 2011 to 2016. Methods: Among 15,792 individuals recruited in ARIC in 1987-1989, 14,357 were free of stroke at baseline and eligible for the present study. Definite or probable stroke events were identified with a computer algorithm and physician reviews. Cases before 1990 were not included. We studied crude incidence rates (per 1,000 person-years) stratified by 5-year periods for age group and 3-year calendar period of follow-up. Temporal trends in rates were estimated using Poisson regression incidence rate ratios adjusted for age, gender, race-center, and time-varying hypertension, diabetes, coronary heart disease, cholesterol lowering medication use and smoking. Results: In ARIC, 1,279 incident strokes occurred over 320,089 person-years among 14,357 participants. Five age-groups were studied: 65-69, 70-74, 75-79, 80-84 and ≥85. Length of follow-up periods differed by age-group as ARIC is a closed cohort. In the 75-79 years old, representative for groups with long follow-up, crude incidence rates (95% CI) per 1,000 person-years decreased from 10.37 (7.11-15.13) in 1999-2001 to 6.58 (4.93-8.79) in 2011-2013 and 5.67 (4.16-7.73) in 2014-2016. Decreasing incidence rates were observed in the analysis by gender and race as well. Linear trends in incidence rate ratios for 3-year periods showed a decrease in adjusted stroke incidence rates from 1990 to 2016 in ARIC participants ≥65 years old (Figure). Conclusions: Validated total stroke incidence rates among ≥65 years old decreased over calendar time in the ARIC cohort. The decrease in rates reported to 2011 extends for the subsequent 5 years (to 2016) in men and women, whites and African-Americans.
Feasibility of chemoradiotherapy in rectal cancer patients with peritumoral abscesses and fistulas: A case-control non-inferiority trial
Authors: V. Ivanov, S. Gordeyev, Z. Mamedli, M. Chernykh, A. Perevoschikov, Y. Surayeva, P. Bulychkin, G. Haqverdiyeva
Journal: Annals of Oncology (2019)
Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Authors: K. Alshammari, K.L. Aung, T. Zhang, A.R.R. Albiruni, S. Serra, T. Stockley, L. Wang, J. Nguyen, A. Spreafico, A.R. Hansen, D. Zwir, L.L. Siu, P. Bedard
Journal: Annals of Oncology (2019)
AVAPLUS: Impact of geriatric assessment on first-line treatment duration (TD) and progression free survival (PFS) in mCRC patients ≥ 70 years
Authors: L. Decoster, C. Kenis, B. Naessens, G. Houbiers, M. De Man, G. Lambecht, E. Monsaert, V. Moons, P. Vergauwe, H. Prenen, E. Van Cutsem, E. Beutels, D. Frijns, H. Wildiers
Journal: Annals of Oncology (2016)
Biomarker testing of lung cancer in Spain
Authors: D. Rodriguez Abreu, M. Guirado, C.J. Camps Herrero, J. Bosch Barrera, R. Bernabé, J. Casal, M.-R. García-Campelo, J.L. Gonzalez-Larriba, B. Massuti Sureda, A.L. Ortega Granados, M. Domine Gomez, M.A. Sala, A. Padilla, E. Del Barco Morillo, J.M. Oramas Rodriguez, R. Blanco Guerrero, D. Aguiar Bujanda, R. López Castro, E. Carcereny Costa, M. Provencio
Journal: Annals of Oncology (2019)
Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Authors: R. Kizawa, Y. Miura, Y. Oda, Y. Nagaoka, J. Masuda, Y. Ozaki, C. Kondoh, S. Moriguchi, Y. Takahashi, K. Ogawa, Y Tanabe Hashimoto, S. Taniguchi, T. Okaneya, A. Kishi, N. Hayashi, H. Takaya, T. Takano
Journal: Annals of Oncology (2019)
Validation of GAME score risk groups in resected colorectal cancer liver metastases and the prognostic relevance of KRAS, NRAS and BRAF mutation analysis
Authors: B. Martin-Cullell, C. Fumagalli, R. Teres, P Gallardo Melo, A Sebio Garcia, A C Virgili Manrique, O. Mirallas, S Sánchez Cabús, V. Molina, J. Szafranska, D Paez Lopez Bravo
Journal: Annals of Oncology (2019)
Benefit of prostate radiotherapy for patients with lymph node only or &lt; 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1|RT comparison”
Authors: S.A. Ali, A. Hoyle, N.D. James, C. Parker, C. Brawley, G. Attard, H. Douis, M.D. Mason, M.K.B. Parmar, M.R. Sydes, N.W. Clarke
Journal: Annals of Oncology (2019)
Exploring anxiety, depression and quality of life of ambulatory cancer patients during chemotherapy
Authors: T. Adamakidou, A. Papadopoulou, O.D. Govina, M. Mantzorou, P. Apostolara, M. Drakopoulou, A. Mantoudi, T. Konstantinidis, C. Tsiou
Journal: Annals of Oncology (2019)
Rheumatic "Activity" as Judged by the Presence of Aschoff Bodies in Auricular Appendages of Patients with Mitral Stenosis
Authors: J. P. DECKER, C. VAN Z. HAWN, S. L. ROBBINS
Journal: Circulation (1953)

Left auricular appendages from 183 patients, removed at operation for mitral stenosis, have been studied with regard to presence of Aschoff bodies and endocardial thrombi. An over-all incidence of Aschoff lesions of 40 per cent was found. There was a significant decrease in Aschoff lesions in the presence of thrombosis. The occurrence of Aschoff bodies in the appendages is correlated with the findings in the remainder of the heart in autopsied cases.
YKL-40 and CA 125 serum levels in patients with ovarian cancer
Authors: A. Chudecka-Glaz, D. Zielinska, I. Rzepka-Górska
Journal: Journal of Clinical Oncology (2009)

e16579 Background: CA 125 is known and useful marker in diagnosis and follow up of patients with ovarian cancer. But there is only a few study about YKL-40 and its usefulness in these patients. The aim of our study was to compare the serum levels of YKL-40 and CA 125 in patients with active phase of ovarian cancer disease (during diagnosis and recurrence). Methods: We analyzed 58 women with ovarian cancer hospitalized and treatment in period from January 2006 to March 2008. Group I - 42 patients constituted women with actually diagnosed ovarian cancer and group II women with recurrence of ovarian cancer. Results: Mean value of YKL-40 in patients with just diagnosed ovarian cancer was 181 ng/mL (16.42–766.1 ng/ml). Mean value of YKL-40 in patients with the recurrent of ovarian cancer was 122.38 ng/mL (9.47–389.22 ng/mL). CA 125 respectively 729.58 U/mL (10.62–4882.1 U/mL) and 579.15 /mL (5.38–6000 U/mL). When the cut-off level for YKL-40 was set at 130 ng/mL we found elevated serum levels in 50% of group I and 38% of group II. Respectively in group I we found 73% elevated values of YKL-40 and 44% in group II when the cut-off level was set at 61 ng/mL. In patients with diagnosed ovarian cancer percentage of elevated CA 125 serum value was 90% and 55% in recurrent ovarian cancer (cut-off level -35 U/mL). Conclusions: Significance of YKL-40 tumor marker in ovarian cancer diagnosis seems to be less then known CA 125 antigen. No significant financial relationships to disclose.
Diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries
Authors: R. Giles, D. Maskens, R. Bick, R. Martinez, M. Packer, A. Bex, D.Y.C. Heng, J.M.G. Larkin, S.J. Maclennan, M. Jewett, E. Jonasch
Journal: Annals of Oncology (2019)
Tumor-Derived Thymic Stromal Lymphopoietin Expands Bone Marrow B-cell Precursors in Circulation to Support Metastasis
Authors: Emeline Ragonnaud, Kanako Moritoh, Monica Bodogai, Fedor Gusev, Soizic Garaud, Chen Chen, Xin Wang, Tuvshintugs Baljinnyam, Kevin G. Becker, Robert W. Maul, Karen Willard-Gallo, Evgeny Rogaev, Arya Biragyn
Journal: Cancer Research (2019)

Abstract Immature B cells in the bone marrow emigrate into the spleen during adult lymphopoiesis. Here, we report that emigration is shifted to earlier B-cell stages in mice with orthotopic breast cancer, spontaneous ovarian cancer, and possibly in human breast carcinoma. Using mouse and human bone marrow aspirates and mouse models challenged with highly metastatic 4T1 breast cancer cells, we demonstrated that this was the result of secretion of thymic stromal lymphopoietin (TSLP) by cancer cells. First, TSLP downregulated surface expression of bone marrow (BM) retention receptors CXCR4 and VLA4 in B-cell precursors, increasing their motility and, presumably, emigration. Then, TSLP supported peripheral survival and proliferation of BM B-cell precursors such as pre-B–like cells. 4T1 cancer cells used the increased pool of circulating pre-B–like cells to generate metastasis-supporting regulatory B cells. As such, the loss of TSLP expression in cancer cells alone or TSLPR deficiency in B cells blocked both accumulation of pre-B–like cells in circulation and cancer metastasis, implying that the pre-B cell–TSLP axis can be an attractive therapeutic target. Significance: Cancer cells induce premature emigration of B-cell precursors from the bone marrow to generate regulatory B cells.
Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
Authors: I.B. Vergote, N. Concin, M.R. Mirza, A. Malmberg, L. Eaton, L. Nicacio, D. Lorusso, I. Soumaoro, B.J. Monk, D.M. O’Malley
Journal: Annals of Oncology (2019)
Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition
Authors: Deepak Perumal, Violetta V. Leshchenko, Pei-Yu Kuo, Zewei Jiang, Ben Readhead, Caroline Eden, Sai Krishna Athaluri Divakar, Weijia Zhang, Hearn Jay Cho, Ajai Chari, M.V.Ramana Reddy, E. Premkumar Reddy, Joel Dudley, Sundar Jagannath, Samir Parekh
Journal: Blood (2014)
Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Authors: M. Vos, M.P.A. Starmans, M.J. Timbergen, S.R. van der Voort, G.A. Padmos, W. Kessels, W.J. Niessen, G J L H van Leenders, D.J. Grünhagen, S. Sleijfer, C. Verhoef, S. Klein, J.J. Visser
Journal: Annals of Oncology (2019)
Methicillin-Resistant<i>Staphylococcus aureus</i>*
Authors: E. Jack Benner, Virginia Morthland
Journal: New England Journal of Medicine (1967)

THE number of patients with infections caused by methicillin-resistant, coagulase-positive strains of Staphylococcus aureus in Europe has increased,1 2 3 and the recent detection of similar strains in Seattle,4 , 5 Chapel Hill, North Carolina, Columbia, South Carolina, Houston, Texas, and New York City indicates that such resistant strains may become as prevalent in this country as they are elsewhere. These strains are usually resistant to penicillin, methicillin, erythromycin, chloramphenicol, tetracycline and kanamycin, and patients infected often die in spite of antibiotic treatment.3 Bulger,5 who found in vitro synergism by kanamycin and cephalothin against 9 strains of Staph. aureus that were resistant to methicillin, . . .
Association of Restrictive Housing During Incarceration With Mortality After Release
Authors: Lauren Brinkley-Rubinstein, Josie Sivaraman, David L. Rosen, David H. Cloud, Gary Junker, Scott Proescholdbell, Meghan E. Shanahan, Shabbar I. Ranapurwala
Journal: JAMA Network Open (2019)

Restrictive housing, otherwise known as solitary confinement, during incarceration is associated with poor health outcomes.To characterize the association of restrictive housing with reincarceration and mortality after release.This retrospective cohort study included 229 274 individuals who were incarcerated and released from the North Carolina prison system from January 2000 to December 2015. Incarceration data were matched with death records from January 2000 to December 2016. Covariates included age, number of prior incarcerations, type of conviction, mental health treatment recommended or received, number of days served in the most recent sentence, sex, and race. Data analysis was conducted from August 2018 to May 2019.Restrictive housing during incarceration.Mortality (all-cause, opioid overdose, homicide, and suicide) and reincarceration.From 2000 to 2015, 229 274 people (197 656 [86.2%] men; 92 677 [40.4%] white individuals; median [interquartile range (IQR)] age, 32 years [26-42]), were released 398 158 times from the state prison system in North Carolina. Those who spent time in restrictive housing had a median (IQR) age of 30 (24-38) years and a median (IQR) sentence length of 382 (180-1010) days; 84 272 (90.3%) were men, and 59 482 (63.7%) were nonwhite individuals. During 130 551 of 387 913 incarcerations (33.7%) people were placed in restrictive housing. Compared with individuals who were incarcerated and not placed in restrictive housing, those who spent any time in restrictive housing were more likely to die in the first year after release (hazard ratio [HR], 1.24; 95% CI 1.12-1.38), especially from suicide (HR, 1.78; 95% CI, 1.19-2.67) and homicide (HR, 1.54; 95% CI, 1.24-1.91). They were also more likely to die of an opioid overdose in the first 2 weeks after release (HR, 2.27; 95% CI, 1.16-4.43) and to become reincarcerated (HR, 2.16; 95% CI, 1.99-2.34).This study suggests that exposure to restrictive housing is associated with an increased risk of death during community reentry. These findings are important in the context of ongoing debates about the harms of restrictive housing, indicating a need to find alternatives to its use and flagging restrictive housing as an important risk factor during community reentry.
FRI-351-DNA methylation pattern of TM6SF2 influences NAFLD progression in genotype-dependent manner
Authors: Burge Ulukan, Buket Yigit, Onur Yilmaz, Melis Cansu Comert, Mert Erkan, Gupse Adali, Murat Dayangac, Mujdat Zeybel
Journal: Journal of Hepatology (2019)
The protease contribution to head and neck squamous cell carcinoma
Authors: Angela Stokes, Mark Pitchers, D. J. Premachandra, Craig Martin, Denise Smith, Helen James, Dylan Edwards
Journal: Cancer Research (2005)

4207  We are investigating the contribution of proteases such as the matrix metalloproteinases (MMPs), their tissue inhibitors (TIMPs), the ADAMs (A Disintegrin and metalloproteinase) and ADAM-TSs (ADAMs with thrombospondin motifs) in head and neck squamous cell carcinoma (HNSCC). The MMPs are a family of proteolytic enzymes that have often been reported to show aberrant gene expression, in a wide range of cancers. They have been implicated at many levels of carcinogenesis, due to their roles in cell growth, differentiation, apoptosis, migration, invasion, angiogenesis and immune surveillance. There have been many studies of the MMPs in HNSCC, however these have tended to focus mainly on only those MMPs involved in invasion and metastasis, even then these results have a propensity to be contradictory. There has, to date, been no comprehensive study of all the MMPs in HNSCC. Using real time polymerase chain reaction (PCR), the MMPs, TIMPs, ADAMs, and ADAM-TSs were comprehensively profiled for their genetic expression in HNSCC tissues. The matched normal, margin of tumor, and centre of tumor tissue samples from forty consented HNSCC patients were collected in collaboration with the Norfolk and Norwich University Hospital Human Tissue Bank. This work has identified many proteases which have significantly changing expression between normal, margin, and centre sample sites. For example, an increase in expression of MMP 1, 9, 11, 14, ADAM 8, 12 and ADAM-TS 2 and a decrease in TIMP 4, ADAM-TS 9 and 10 in the centre and margin compared to normal. These results not only clarify and confirm existing knowledge of the protease contribution to HNSCC but, also show significant changes in genes such as ADAMs and ADAM-TSs which have, to date, not been studied in these tissue types. HNSCC is a disease of high morbidity and mortality. The poor prognosis of these patients is due to the high invasive and metastatic potential of these tumors, the high recurrence rates and the low treatment responses. This means that the five-year survival rate for HNSCC is currently only 50% and this has remained static for over 20 years. Knowledge of the protease contribution to this disease may help identify markers predictive of disease, treatment response and prognosis, which may lead to a much needed increase in the survival of these patients. This work is supported by the Big C Appeal, the Anthony Long Charitable Trust, and the EU Framework 6 (LSHC-CT-2003-503297).